SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com/.
Cerus Corporation (Nasdaq: CERS) $3.08. Today announced results of 22 abstracts presenting experiences with the INTERCEPT Blood System for platelets, plasma and red blood cells during the XXXIst International Congress of the International Society for Blood Transfusion in Berlin, Germany held from June 26 to July 1. Studies included data collected in Spain, France, Germany, Italy, Belgium, Sweden, Luxembourg and Scotland, covering a broad range of topics from in vitro results of routine validations to therapeutic efficacy of treated platelets.
"These studies underscore the growing use of INTERCEPT pathogen inactivation by blood centers in many European countries, and reflect our consistent experience that the platelet and plasma treatment processes are rapidly and successfully integrated into routine production," said Dr. Laurence Corash, Cerus' chief medical officer. "The INTERCEPT red blood cell study published in collaboration with German Red Cross researchers demonstrates our progress toward designing a treatment process that can complement our platelet and plasma products and maintain a similar user experience for pathogen inactivation of red blood cells in the future."
What They Do: Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.
ADVENTRX Pharmaceuticals (AMEX: ANX) $1.61. Today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site. The 9-month stability data are on track to support the submission of a New Drug Application (NDA) for Exelbine.
"These results are consistent with our expectations and what we anticipate from the 12-month data," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Once the 12-month data is analyzed, we will prepare and submit the Exelbine NDA, which we expect will take place in the fourth quarter of this year."
What They Do: ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.
Response Genetics (RGDX) $2.38. Today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer (NSCLC). These rearranged genes promote tumor cell growth and predict lack of benefit from therapies that inhibit EGF receptor (EGFR) activity.
Recently, ALK inhibitors have entered clinical development and shown efficacy in NSCLC patients harboring EML4-ALK fusion proteins. Response Genetics’ proprietary PCR-based assay is capable of rapidly detecting and identifying nine known fusion gene variants in archival tissue. This new test is expected to be useful for large-scale screening of tissue samples and is available nationwide through the company’s sales force.
What They Do: Response Genetics Inc. (“RGI”) is focused on the development and sale of molecular diagnostic tests for cancer.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
